Synlogic Inc (NASDAQ:SYBX) has been given an average rating of “Buy” by the eight analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $19.40.
A number of research firms have commented on SYBX. HC Wainwright set a $20.00 price target on shares of Synlogic and gave the stock a “buy” rating in a research report on Tuesday. Wedbush restated an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. Oppenheimer initiated coverage on shares of Synlogic in a research report on Friday, June 29th. They set an “outperform” rating and a $18.00 price target on the stock. reiterated a “buy” rating and issued a $18.00 target price on shares of Synlogic in a report on Tuesday, July 3rd. Finally, Zacks Investment Research upgraded shares of Synlogic from a “hold” rating to a “buy” rating and set a $8.50 target price on the stock in a report on Tuesday, August 14th.
In related news, insider Paul Francis Miller sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $13.05, for a total value of $39,150.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 12,000 shares of company stock worth $139,110 over the last quarter. Insiders own 23.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYBX. Dynamic Technology Lab Private Ltd bought a new stake in shares of Synlogic in the 1st quarter worth approximately $120,000. DRW Securities LLC acquired a new stake in shares of Synlogic during the first quarter valued at approximately $178,000. Element Capital Management LLC acquired a new stake in shares of Synlogic during the first quarter valued at approximately $182,000. Northern Trust Corp acquired a new stake in shares of Synlogic during the first quarter valued at approximately $249,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Synlogic during the first quarter valued at approximately $538,000. Institutional investors and hedge funds own 79.39% of the company’s stock.
Shares of SYBX stock traded down $0.37 during midday trading on Friday, reaching $9.74. 145,115 shares of the company were exchanged, compared to its average volume of 137,510. Synlogic has a 12 month low of $7.27 and a 12 month high of $18.36. The company has a market capitalization of $361.37 million, a price-to-earnings ratio of -1.66 and a beta of 1.69.
Synlogic (NASDAQ:SYBX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.06). Synlogic had a negative return on equity of 43.51% and a negative net margin of 5,949.04%. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.22 million. As a group, sell-side analysts anticipate that Synlogic will post -2.47 EPS for the current year.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Further Reading: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.